These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6112618)

  • 1. Oral treatment of haemophilia a by factor VIII bound to chylomicra.
    Paulssen MM; van Pelt BC
    Lancet; 1981 Jun; 1(8233):1310. PubMed ID: 6112618
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral treatment of haemophilia.
    Austen DE; Rizza CR
    Lancet; 1981 Aug; 2(8242):359. PubMed ID: 6115125
    [No Abstract]   [Full Text] [Related]  

  • 3. A successful physiotherapy management case of a patient with acquired haemophilia A prior to factor VIII inhibitor eradication.
    Goto M; Haga N; Yokota K; Takamizawa K; Takedani H
    Haemophilia; 2016 May; 22(3):e228-31. PubMed ID: 26988340
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-factor-VIII inhibitors in haemophilia.
    Lancet; 1989 Aug; 2(8659):363-4. PubMed ID: 2569554
    [No Abstract]   [Full Text] [Related]  

  • 5. [Changed distribution of hemophilia preparations diminishes the risks of infection transmission].
    Eklund LH
    Lakartidningen; 1990 Oct; 87(40):3196. PubMed ID: 2122141
    [No Abstract]   [Full Text] [Related]  

  • 6. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder.
    Brackmann HH; Gormsen J
    Lancet; 1977 Oct; 2(8044):933. PubMed ID: 72276
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?
    Siegmund B; Richter H; Pollmann H
    Haemophilia; 2005 Nov; 11(6):638-41. PubMed ID: 16236116
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral treatment of haemophilia A by gastrointestinal absorption of factor VIII entrapped in liposomes.
    Hemker HC; Hermens WT; Muller AD; Zwaal RF
    Lancet; 1980 Jan; 1(8159):70-1. PubMed ID: 6101418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: recombinant active factor VII concentrate].
    Udvardy M
    Orv Hetil; 1998 Sep; 139(38):2255-8. PubMed ID: 9775655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful management of massive intraperitoneal bleeding in a hemophilia A patient with inhibitor by surgical debridement of the incomplete hematoma and administration of recombinant factor VIII and activated factor VII.
    Koyama T; Nagao T; Tsunozaki H; Arai M; Miura O
    Pathophysiol Haemost Thromb; 2006; 35(5):405-7. PubMed ID: 17230044
    [No Abstract]   [Full Text] [Related]  

  • 11. Neonatal immune tolerance for hemophilia: can we "tolerate" new paradigms for gene therapy trials?
    Monahan PE
    J Thromb Haemost; 2007 Sep; 5(9):1801-4. PubMed ID: 17723117
    [No Abstract]   [Full Text] [Related]  

  • 12. Prospective study of continuous infusion with Beriate® P in patients with severe haemophilia A undergoing surgery - a subgroup analysis.
    Auerswald G; Bade A; Johne J; Haubold K; Overberg D; Masurat S; Moorthi C
    Thromb Res; 2014 Nov; 134 Suppl 1():S43-7. PubMed ID: 24360932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor.
    Peerlinck K; Vermylen J
    Thromb Haemost; 1999 Dec; 82(6):1775-6. PubMed ID: 10613674
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral therapy for haemophilia.
    Morgenthaler JJ
    Lancet; 1980 Mar; 1(8167):546. PubMed ID: 6102269
    [No Abstract]   [Full Text] [Related]  

  • 15. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
    Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.
    Allen GA; Hoffman M; Roberts HR; Monroe DM
    Br J Haematol; 2006 Aug; 134(3):314-9. PubMed ID: 16787497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer.
    Franchini M; Capra F; Capelli C; de Maria E; Lippi G; Gandini G
    Haematologica; 2001 Apr; 86(4):E12. PubMed ID: 11325664
    [No Abstract]   [Full Text] [Related]  

  • 18. Does peroral administration of factor VIII induce oral tolerance in patients with acquired haemophilia A?
    Lindgren A; Wadenvik H; Tarkowski A; Tengborn L
    Thromb Haemost; 2000 Apr; 83(4):632-3. PubMed ID: 10780332
    [No Abstract]   [Full Text] [Related]  

  • 19. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.
    Morfini M; Auerswald G; Kobelt RA; Rivolta GF; Rodriguez-Martorell J; Scaraggi FA; Altisent C; Blatny J; Borel-Derlon A; Rossi V
    Haemophilia; 2007 Sep; 13(5):502-7. PubMed ID: 17880436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.